Factors influencing survival of 107 HER2 positive breast cancer patients treated with trastuzumab based neoadjuvant chemotherapy

被引：1
|
作者：
Favier, L. [1 ]
Guiu, S. [1 ]
Dunach, E. [1 ]
Assous, D. [1 ]
Bonnetain, F. [1 ]
Gligorov, J. [2 ]
Stockmeier, V. [3 ]
Vasseur, B. [4 ]
Fumoleau, P. [1 ]
Coudert, B. [1 ]
机构：
[1] Ctr Georges Francois Leclerc, Dijon, France
[2] Hop Tenon, F-75970 Paris, France
[3] Lab Sanofi Aventis, Paris, France
[4] Lab Roche, Paris, France
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70820-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5058
引用
收藏
页码：201 / 201
页数：1
相关论文
共 50 条
  • [21] HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
    Lee, Hee Jin
    Seo, An Na
    Kim, Eun Joo
    Jang, Min Hye
    Suh, Koung Jin
    Ryu, Han Suk
    Kim, Yu Jung
    Kim, Jee Hyun
    Im, Seock-Ah
    Gong, Gyungyub
    Jung, Kyung Hae
    Park, In Ae
    Park, So Yeon
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 142 (06) : 755 - 766
  • [22] Is HER2 loss after neoadjuvant chemotherapy determinant for the choice of adjuvant treatment in HER2 positive breast cancer patients?
    Altundag, Kadri
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (02) : 328 - 328
  • [23] Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab
    Junichi Kurebayashi
    Naoki Kanomata
    Tetsumasa Yamashita
    Toshiro Shimo
    Akiko Mizutoh
    Takuya Moriya
    Hiroshi Sonoo
    Breast Cancer, 2015, 22 : 292 - 299
  • [24] Prediction of response to neoadjuvant chemotherapy in HER2 positive breast cancer by MammaTyper®
    Scatena, C.
    Belcastro, E.
    Scarpitta, R.
    Naccarato, A. G.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 30 - 30
  • [25] HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment
    Altundag, Kadri
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (01) : 261 - 261
  • [26] HER2 positive breast cancer patients having HER2 loss after neoadjuvant chemotherapy should still be treated with adjuvant anti-HER2 treatment
    Kadri Altundag
    Breast Cancer Research and Treatment, 2019, 175 : 261 - 261
  • [27] Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?
    Silvia Antolín
    Lucía García-Caballero
    Cristina Reboredo
    Aurea Molina
    Joaquín Mosquera
    Ángel Vázquez-Boquete
    Rosalía Gallego
    Mari Paz Santiago
    Ángel Concha
    Eva Pérez
    Lourdes Calvo
    Tomás García-Caballero
    Virchows Archiv, 2021, 479 : 853 - 857
  • [28] Significance of HER2 Status in Neoadjuvant Chemotherapy for Breast Cancer Patients
    Wang, Chengqin
    Xing, Xiaoming
    Chen, Zhaoxu
    Wei, Zhimin
    Li, Yujun
    LABORATORY INVESTIGATION, 2023, 103 (03) : S226 - S228
  • [29] Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?
    Antolin, Silvia
    Garcia-Caballero, Lucia
    Reboredo, Cristina
    Molina, Aurea
    Mosquera, Joaquin
    Vazquez-Boquete, Angel
    Gallego, Rosalia
    Santiago, Mari Paz
    Concha, Angel
    Perez, Eva
    Calvo, Lourdes
    Garcia-Caballero, Tomas
    VIRCHOWS ARCHIV, 2021, 479 (04) : 853 - 857
  • [30] Prognostic implications of HER2 change after neoadjuvant chemotherapy in HER2-positive breast cancer patients
    Sato, A.
    Maeda, Y.
    Matsumoto, A.
    Ikeda, T.
    Jinno, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1409 - S1409
12345